With all the turmoil surrounding the pandemic, it's sad to think about all the illness that still transpired outside of actually catching CV

SmallCapFirm

Low Float Nasdaq Profile (TCBP) Has Key Positive Interim Data In March, 5 Potential Catalysts To Know

March 17th

SCF Readers,

With all the turmoil surrounding the pandemic, it's sad to think about all the illness that still transpired outside of actually catching CV19.

Long story short, cancer hasn't gone anywhere.

In fact the global cancer therapeutics market size was valued at $98Bn in 2018 and is estimated to reach $180.1Bn by 2026 according to Allied Market Research.

With so much growth potential within the market, it's important to look at under-the-radar companies who may not yet have the biggest fanbase on Wall Street quite yet.

I've uncovered one such company who could be on the verge of making a name for themselves in the near future.

And based on several potential catalysts including a low float, oversold leaning technicals, a recent Nasdaq uplisting and more, you'll want to get this idea on your watch-list quickly.

For Thursday, March 17th, there is only one company to be watching above all others:

*TC Biopharm (Holdings) Plc (Nasdaq: TCBP)*

image

TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer and viral infections with human efficacy data in acute myeloid leukemia.

Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma delta t-cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.

TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune in treatment of acute myeloid leukemia and Phase I trial for ImmuniStim in treatment of CV19 patients using the Company's proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide.

TC BioPharm also maintains a robust pipeline for future indications in solid tumors and other aggressive viral infections as well as a significant IP/patent portfolio in the use of CARs with gamma delta t-cells and owns our manufacturing facility to maintain cost and product quality controls.

And right now, the TCBP has 5 potential catalysts that could fuel a near term move for this profile:

No. 1 - Positive Interim Data From Phase 1a/2b Study

No. 2 - A Low Float Profile

No. 3 - Oversold Leaning Technicals Could Signal Reversal Potential

No. 4 - Company Uplists To Nasdaq, Could Draw Significant New Attention

No. 5 - New Board Members Provide Invaluable Experience

But more on those in a second...

TCBP Lead Pipeline Program

The company's broad platform technology allows them to design specific therapies to treat a broad range of cancers and infectious diseases with "off the shelf” allogeneic gamma delta T cell (GDT) products. Unlike other CAR-T platforms, destruction of target cells is controlled by the innate endogenous kill-switch, augmented by power of synthetic transgenes for more effective targeting and armoring. Tolerance of off-tumor target expression allows for targeting of tumor-associated antigens previously considered impossible.

Their stepwise approach to clinical development has enabled TC BioPharm to take a logical, safer and more agile approach to their clinical trials. By starting with an autologous, unmodified gamma delta product, they were able to establish safety prior to entering the clinic in 2018 with their unmodified allogeneic product. Now, their focus is on clinical development and refinement of products based on the ideal GDT vehicle with a proprietary genetic CAR-T arsenal to fight a range of cancers.

image

About OmnImmune®

OmnImmune® an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells. The trial, for treatment of patients suffering from relapse/refractory Acute Myeloid Leukemia (AML), OmnImmune® comprises GDT cells sourced from healthy donors, expanded and activated in large numbers before being purified and formulated for infusion into patients. OmnImmune® is a frozen and thawed product, now "banked" from donor derived cells. Phase 2/3 trials will begin enrollment in the first quarter of 2022 in the UK with expansion into the US in 2022.

More key details from the company website.

And right now, TCBP has 5 potential catalysts that could spark a near term vertical chart move. Here's what to know:

No. 1 TCBP Potential Catalyst - Positive Interim Data From Phase 1a/2b Study

TC BioPharm Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells

-Complete and near complete responses (morphologic leukemia-free state) observed with OmnImmune® starting at lowest dose level in Phase 1b/2a study for the treatment of relapsed/refractory acute myeloid leukemia

-Results yielded no related serious adverse events, including no Graft v Host Disease, neurotoxicity or cytokine release syndrome at any dose level-Allogeneic product can be stored frozen and used as an 'off-the-shelf' cell therapy

EDINBURGH, Scotland, March 8, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announces positive interim data its Phase 1a/2b human study evaluating safety and tolerability of TCB-002, OmnImmune®, the Company's allogeneic unmodified gamma delta t-cell product, a novel therapeutic targeting the potential treatment of relapse/refractory Acute Myeloid Leukemia ("AML").

image

7 patients received treatment and 2 patients (enrolled in the low dose cohort) did not reach day 28 assessment and were not evaluable for efficacy per protocol with the third patient being available for safety inclusion but not efficacy.

Of the 7 patients treated, three received OmnImmune®, at a low-dose and four received OmnImmune®, at a higher dose of cells. In the low dose cohort one patient achieved MLFS (morphologic leukemia-free state), one patient achieved stable disease characterized as near complete response and one patient met safety endpoints but was lost to follow-up due to disease co-morbidity (bilateral pneumonia unrelated to OmnImmune® treatment). In the higher dose cohort, 50% of patients achieved complete responses, one patient had progressive disease and one patient exhibited significantly reduced cancer blast count at day fourteen (prior to the study being cut short due to CV19).

"We are extremely pleased to receive such positive data from our phase 1b/2a study demonstrating OmnImmune® as safe and tolerable among patients with advanced acute Myeloid Leukemia," said Bryan Kobel, Chief Executive Officer of TC BioPharm. "These results underline OnmImmune's potential in becoming a viable AML treatment. We look forward to reporting additional phase 2/3 clinical data during the first half of 2022."

"These results are very encouraging in such late-stage unresponsive patients, most of whom had very advanced cancer, were fourth or fifth line with no further therapeutic options," said Dr. Sebastian Wanless, Senior Clinical Director at TC BioPharm. "OmnImmune® comprises allogeneic gamma delta T cells sourced from healthy donors, expanded and activated in large numbers before being purified and formulated for infusion into patients. Our Phase 2b/3 trial will take this therapeutic another step further, incorporating our frozen/thawed product generated from our proprietary universal cell banks of gamma deltas, for a true off the shelf allogeneic cell therapy. During 2022 we plan to evaluate OmnImmune® efficacy in unresponsive first-line of treatment AML patients and expand our clinical trial efforts into multiple blood cancer indications."

Allogeneic gamma-delta T cell persistence was evaluated in two patients treated. In one patient allogenic product remained detectable after 100 days following three infusions. Another patient demonstrated haematological recovery with sustained elevation in key immune cells over 100 days following the initial infusion.

Clinical data provided evidence of good safety and tolerability profile of OmnImmune® as no product related safety concerns were raised during Safety Review Committee meetings. Moreover, no graft vs host disease, immune effector cell-associated neurotoxicity syndrome or cytokine release syndrome was reported in any of the treated patients.

The two patients exhibiting complete response and stable disease were re-dosed with allogeneic product, and the patient with and morphologic leukemia-free state received two further infusions of OmnImmune®. No toxicities were documented following these repeat infusions.

Dr. Michael Leek, Founder and Executive Chairman commented, "Apart from matched bone-marrow stem cell transplants, patients with unresponsive AML are presented with few viable treatment options. At TC BioPharm we are developing affordable allogeneic cell therapies for blood cancers such as AML, we believe such cell therapies will become a future mainstream standard of care for hematological malignancies."

Read the full article here.

-----

No. 2 TCBP Potential Catalyst - A Low Float Profile

According to the Yahoo Finance website, TCBP has a low float.

The website reports this profile to have approximately 9.92Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.

-----

No. 3 TCBP Potential Catalyst - Oversold Leaning Technicals Could Signal Reversal Potential

As of close on Wednesday, Barchart was reporting this profile to have several oversold leaning technicals.

These technicals could be signaling a healthy reversal in the near term.

Here's the definition of a "reversal" from Investopedia:

"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."

Now, here are some key technicals (as of close Wednesday) that could signal TCBP to be leaning oversold and on the verge of a potential reversal.

  • 9-Day Relative Strength Index: 37.47%
  • 14-Day Relative Strength Index: 30.40%

When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.

  • 14-Day Raw Stochastic: 21.37%
  • 14-Day Williams %R: 78.63%

As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.

Keep an eye on these technicals closely.

-----

No. 4 TCBP Potential Catalyst - Company Uplists To Nasdaq, Could Draw Significant New Attention

TC BioPharm Begins Trading on Nasdaq Today Under Symbol "TCBP"

- Listing highlights TC BioPharm's vertically integrated cell therapy platform, in-house manufacturing and R&D capabilities

- Company is at a pivotal stage in growth cycle with pending clinical results for the treatment of Acute Myeloid Leukemia

EDINBURGH, Scotland, Feb. 11, 2022 /PRNewswire/ -- TC BioPharm (Holdings) plc ("TC BioPharm"), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications is pleased to announce that American Depositary Shares representing the Company's ordinary shares will commence trading today on the Nasdaq Capital Market (the "Nasdaq") under the ticker symbol "TCBP".

[...]

"Listing to the Nasdaq is an important milestone for TC BioPharm and serves as a testament to our ability to build a platform technology for universal off-the-shelf therapy using gamma-delta T Cells," said CEO, Bryan Kobel. "Trading on the Nasdaq grants us access to one of the world's largest capital markets and will enhance our visibility in the marketplace, and ultimately unlock shareholder value."

Read the full article here.

-----

No. 5 TCBP Potential Catalyst - New Board Members Provide Invaluable Experience

TC Biopharm Announces Appointment of New Board Members

EDINBURGH, Scotland, Feb. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, is pleased to announce the appointment of 4 new members to its Board of Directors.

Joining the board are Mark Bonyhadi, James Culverwell, Arlene Morris and Edward Niemczyk. The new additions became effective upon completion of TC BioPharm's recent IPO. These appointments bring the Company's total board membership to 7.

"We are excited to welcome these new independent directors to our Board," said Bryan Kobel, CEO of TC BioPharm. "They bring decades of expertise and leadership in key areas such as dr-ug commercialization, capital markets and strategic implementation. I am confident that they will provide valuable perspectives as we continue to execute our strategy of developing safe, cost-effective cell therapies for cancer and severe viral infection."

[...]

Read the full article here.

-----

Complete TCBP Recap - 5 Potential Catalysts For This New Nasdaq Profile

No. 1 - Positive Interim Data From Phase 1a/2b Study

No. 2 - A Low Float Profile

No. 3 - Oversold Leaning Technicals Could Signal Reversal Potential

No. 4 - Company Uplists To Nasdaq, Could Draw Significant New Attention

No. 5 - New Board Members Provide Invaluable Experience

-----

Coverage is officially initiated on TCBP. When you have time, do this:

image

Get TCBP on your radar now.

Sincerely,

Axel Adams

Editor, SCF


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). Disclosure: Make sure to always do your own research and due diligence on any day and swing trade profile I bring to your attention. I am not a license d finan.cial advise r. All potential percentage gains are based on from the low to the high of day. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: smallcapfirm.com/disclosure StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaqwirenews . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and Awareness Consulting Network LLC, SmallCapFirm has been hired for a period beginning on 3/17/22 and ending on 3/18/22 to publicly disseminate information about (TCBP) via Website, Email and SMS. SWN Media LLC was paid twenty-two thousand five hundred USD via bank wire transfer. We own zero shares of (TCBP).